Perspective Therapeutics Inc (CATX) Stock Price, Quote & News

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices

Sector: Healthcare

Phone: 206 676 0900

Website: www.perspectivetherapeutics.com

Address:

2401 Elliott Avenue, Suite 320, Seattle, United States

Ace_of_Blue Dec. 4 at 8:08 PM

$CATX God I love this penny stock.

1 · Reply

Xanderzzzzzzz Dec. 4 at 6:36 PM

$CATX still adding 🙏🙏🙏 will sell at $10 at the minimum.. no rush

1 · Reply

Ren_Stimpy Dec. 4 at 4:47 PM

$CATX Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium January 5, 2026 https://perspectivetherapeutics.com/newsroom/press-release?i=160059

1 · Reply

Miura1957 Dec. 4 at 4:30 PM

$CATX ASCO-GI presentation Jan 8-10…posters to be released on the 1/5…presentation by some guy from Mayo…let’s hope this is the catalyst for an exit!

3 · Reply

JDinvestments Dec. 4 at 4:26 PM

$CATX this should be $10 plus conservatively always adding at these low levels STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

bryerchase1986 Dec. 4 at 2:21 PM

$CATX Yeahhh Budddddy!!!!!!!!

0 · Reply

Xanderzzzzzzz Dec. 4 at 12:28 PM

$CATX

1 · Reply

morty104 Dec. 4 at 12:17 PM

$CATX

0 · Reply

Xanderzzzzzzz Dec. 4 at 12:09 PM

$CATX https://perspectivetherapeutics.com/newsroom/press-release?i=160059

0 · Reply

Xanderzzzzzzz Dec. 4 at 12:09 PM

$CATX

0 · Reply

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 11, 2025, 11:11 PM EST - 23 days ago

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 4:05 PM EST - 24 days ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Oct 31, 2025, 7:00 AM EDT - 5 weeks ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 24, 2025, 7:00 AM EDT - 6 weeks ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 20, 2025, 5:05 PM EDT - 6 weeks ago

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Oct 20, 2025, 4:00 AM EDT - 6 weeks ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Sep 3, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Aug 26, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 13, 2025, 6:45 AM EDT - 4 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 2, 2025, 8:53 AM EDT - 4 months ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Jul 24, 2025, 12:45 PM EDT - 4 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 15, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jun 21, 2025, 8:00 AM EDT - 5 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 5 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

May 30, 2025, 5:21 PM EDT - 6 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 12, 2025, 4:36 PM EDT - 7 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 1, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Apr 23, 2025, 12:25 PM EDT - 8 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 8 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 11, 2025, 7:00 AM EDT - 8 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 26, 2025, 4:10 PM EDT - 9 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 17, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 13, 2025, 2:52 PM EDT - 9 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Feb 26, 2025, 7:00 AM EST - 10 months ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 21, 2025, 7:00 AM EST - 10 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 10 months ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Jan 24, 2025, 7:00 AM EST - 11 months ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 6, 2025, 8:00 AM EST - 11 months ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Dec 23, 2024, 11:13 AM EST - 1 year ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 20, 2024, 4:16 PM EST - 1 year ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 11, 2024, 12:05 PM EDT - 1 year ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 2, 2024, 3:11 PM EDT - 1 year ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 12:10 PM EDT - 1 year ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Ace_of_Blue Dec. 4 at 8:08 PM

$CATX God I love this penny stock.

1 · Reply

Xanderzzzzzzz Dec. 4 at 6:36 PM

$CATX still adding 🙏🙏🙏 will sell at $10 at the minimum.. no rush

1 · Reply

Ren_Stimpy Dec. 4 at 4:47 PM

1 · Reply

Miura1957 Dec. 4 at 4:30 PM

$CATX ASCO-GI presentation Jan 8-10…posters to be released on the 1/5…presentation by some guy from Mayo…let’s hope this is the catalyst for an exit!

3 · Reply

JDinvestments Dec. 4 at 4:26 PM

$CATX this should be $10 plus conservatively always adding at these low levels STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

bryerchase1986 Dec. 4 at 2:21 PM

$CATX Yeahhh Budddddy!!!!!!!!

0 · Reply

Xanderzzzzzzz Dec. 4 at 12:28 PM

$CATX

1 · Reply

morty104 Dec. 4 at 12:17 PM

$CATX

0 · Reply

Xanderzzzzzzz Dec. 4 at 12:09 PM

$CATX https://perspectivetherapeutics.com/newsroom/press-release?i=160059

0 · Reply

Xanderzzzzzzz Dec. 4 at 12:09 PM

$CATX

0 · Reply

Motorhhead Dec. 4 at 10:38 AM

$ASST $CATX $CHAI Howdy Doody is getting the Peanut Gallery all fired up over these latest duds lol

1 · Reply

KoalaLion Dec. 3 at 8:26 PM

$CATX Probably the chats at the conferences are going well ;)

0 · Reply

morty104 Dec. 3 at 8:25 PM

$CATX yes! Release the rockets boys and girls!!! Diamond hands and lambos sooooon! HODL!

0 · Reply

bryerchase1986 Dec. 3 at 7:15 PM

$CATX Countdown to liftoff.

1 · Reply

Jclaudiooo Dec. 3 at 6:54 PM

$CATX News?

0 · Reply

Alacrity2 Dec. 3 at 3:44 PM

$CATX oh yay catx sentiments is bearish! This is torture to watch! The huge price targets have been in place for almost a year… when will this happen? I buy when I think it is the bottom and then it slips some more

1 · Reply

morty104 Dec. 3 at 2:58 PM

$CATX ASYSTOLE! Start cpr….epi and atropine stat…get me an airway….

1 · Reply

morty104 Dec. 2 at 9:59 PM

$CATX DOWN GOES FRASIER!!!

0 · Reply

JDinvestments Dec. 2 at 5:41 PM

$CATX at this point I concentrate on how many shares I can own BUYING on the cheap STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🚀

0 · Reply

jive_turkey Dec. 2 at 5:38 PM

$CATX fire side chats today and tomorrow. These never go well.

1 · Reply

Miura1957 Dec. 2 at 5:37 PM

$CATX all indications point to them trying to test the low before the end of the year. Buy if you have the guts, hold on to your shorts if you don’t…decided F it, if it hits $1.60 I’ll buy more, with a target for a full exit by 2Q 2026….

0 · Reply

morty104 Dec. 2 at 5:23 PM

$CATX what was that PT? Can’t even trade at book value….

1 · Reply

Market Cap	152.39M
Revenue (ttm)	1.45M
Net Income (ttm)	-79.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,467.59%
Debt to Equity Ratio	0.01

Volume	1,930,600
Avg Vol	1,647,984
Day's Range	N/A - N/A
Shares Out	74.34M
Stochastic %K	56%
Beta	1.22
Analysts	Strong Sell
Price Target	$11.33